|
See related Pegasys inj information |
|
|
|
Manufacturer |
Roche |
|
Distributor |
Hong Kong: DKSH |
|
Contents |
Recombinant interferon α-2a (40 KD) conjugated to bis-(monomethoxy polyethylene glycol) |
|
Indications |
Treatment of HBeAg+ve or HBeAg-ve chronic hepatitis B & chronic hepatitis C in adults. |
|
Dosage |
Chronic hepatitis B 180 mcg SC once wkly for 48 wk. Chronic hepatitis C Monotherapy 180 mcg SC once wkly for 48 wk. Combination therapy: Genotype 1 patient w/ & w/o RVR <75 kg 180 mcg SC once wkly w/ oral ribavirin 1,000 mg for 48 wk; ≥75 kg 180 mcg SC once wkly w/ oral ribavirin 1,200 mg for 48 wk. Genotype 4 w/ & w/o RVR <75 kg 180 mcg SC once wkly w/ oral ribavirin 1,000 mg for 48 wk; ≥75 kg 180 mcg SC once wkly w/ oral ribavirin 1,200 mg for 48 wk. Treatment for 24 wk may be considered in patients w/ genotype 1 w/ low viral load (LVL) (≤800,000 IU/mL) at baseline w/ RVR & genotype 4 w/ RVR. Genotype 2/3 180 mcg SC once wkly w/ oral ribavirin 800 mg for 24 wk. Treatment for 24 wk may be considered in patients infected w/ Genotype 1 w/ low viral load (LVL) (≤800,000 IU/mL) at baseline w/ RVR & genotype 4 w/ RVR. |
|
Contraindications |
Hypersensitivity. Autoimmune hepatitis; severe hepatic dysfunction or decompensated liver cirrhosis; severe preexisting cardiac disease including unstable uncontrolled cardiac disease in previous 6 mth. HIV-HCV patient w/ cirrhosis & a Child-Pugh score ≥6. Neonates & young childn up to 3 yr. |
|
Special Precautions |
Hypoglycaemia, hyperglycaemia, DM, HTN. Perform baseline & periodic standard haematological & biochem lab tests. Decreased WBC, ANC & platelet count. Concomitant administration of other myelosuppressants. eva luate TSH & T4 levels. Patient w/ anaemia, existence or history of severe psychiatric conditions, preexisting cardiac abnormalities, hepatic decompensation, hypersensitivity reaction, predisposition to autoimmune disorders, fever, infections, ocular & pulmonary changes, psoriasis, transplantation. Loss of teeth. Discontinue nursing prior to initiation of treatment. |
|
Adverse Drug Reactions |
Anorexia, decreased wt, headache, insomnia, irritability, depression, dizziness, concentration impairment, anxiety, dyspnoea, cough, nausea, diarrhoea, abdominal pain, alopecia, pruritus, dermatitis, dry skin, myalgia, arthralgia, fatigue, pyrexia, rigors, inj site reaction, asthenia, pain, neutropenia, thrombocytopenia.
View ADR Monitoring Form |
|
Drug Interactions |
Theophylline, methadone, didanosine (co-administration w/ ribavirin).
View more drug interactions with Pegasys |
|
Pregnancy Category (US FDA) |
Category C: Either studies in animals have revealed adverse effects on the foetus (teratogenic or embryocidal or other) and there are no controlled studies in women or studies in women and animals are not available. Drugs should be given only if the potential benefit justifies the potential risk to the foetus. |
|
Presentation/Packing |
|
Form |
Packing |
Photo |
|
Pegasys injection |
|
Pegasys 135 mcg/0.5 mL x 1's |
 |
|
Pegasys 180 mcg/0.5 mL x 1's |
 |
|
|
|
Manufacturer: |
Roche |
|
Distributor: |
Hong Kong: DKSH
|
|
|
|
